EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Mass Spectrometry-Driven Epitope Mapping: Application of Diethylpyrocarbonate Covalent Labeling for the Immunotherapeutic Target Programmed Cell Death Protein 1

Parawan Ramanandana, Phumrapee Pianpaktr iD, Jiradej Makjaroen, Tossapon Wongtangprasert, Zachary J Kirsch, Eric M Graban, Richard W Vachet iD, Poorichaya Somparn, Trairak Pisitkun iD, Patanachai K Limpikirati iD

Journal of the American Society for Mass Spectrometry · 2025

DOI: 10.1021/jasms.5c00070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Society for Mass Spectrometry, 2025. Verfasst von Parawan Ramanandana und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand. Hauptthemen laut MEDLINE: Epitope Mapping, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Diethyl Pyrocarbonate. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIGMS NIH HHS, Graduate School, Chulalongkorn University, Ministry of Higher Education, Science, Research and Innovation, Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monoclonal antibodies (mAbs) have revolutionized immuno-oncology, with anti-programmed cell death protein 1 (PD1) mAbs emerging as key therapeutic agents in cancer treatment. This study presents the development and application of diethylpyrocarbonate (DEPC) covalent labeling-mass spectrometry (CL-MS) for detailed epitope mapping of anti-PD1 mAbs on PD1. By using DEPC CL-MS, we aimed to identify precise antibody binding sites on PD1 and benchmark its effectiveness against traditional X-ray crystallography. DEPC CL-MS offers high sensitivity and specificity while requiring less sample preparation and shorter analysis times, typically taking days or less, instead of months. PD1 was individually incubated with either nivolumab or a novel anti-human PD1 mAb (CU-MAB), followed by DEPC labeling, to assess DEPC modification extents under both binding and nonbinding conditions using bottom-up LC-MS/MS. Significant changes in DEPC modification at residues S27, S60, S62, S127, and K131 indicated binding sites and conformational shifts upon antibody interaction. These findings showed strong alignment with crystallography (PD1/nivolumab) and AlphaFold structural predictions (PD1/nivolumab and PD1/CU-MAB), highlighting the value of in-solution CL-MS for confirming AlphaFold predictions. This study underscores DEPC CL-MS as an efficient tool for epitope mapping, offering actionable insights into PD1-antibody interactions to drive therapeutic antibody development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epitope MappingProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalDiethyl PyrocarbonateTandem Mass SpectrometryHumansNivolumabBinding Sites, AntibodyEpitopesCrystallography, X-Ray

Stichwörter der Autor:innen

Covalent LabelingDiethylpyrocarbonateEpitope MappingImmuno-OncologyMass SpectrometryMonoclonal AntibodiesNivolumabPD1

Substanzen

Programmed Cell Death 1 ReceptorAntibodies, MonoclonalPDCD1 protein, humanDiethyl PyrocarbonateNivolumabEpitopes

Autor:innen und Institutionen

  • Department of Food and Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand.
  • Pharmaceutical Sciences and Technology (PST) Graduate Program, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand.
  • Center of Excellence in Systems Biology (CUSB), Faculty of Medicine, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Huachiew Chalermprakiet University, Bang Phli, Samut Prakan 10540, Thailand.
  • Department of Transfusion Medicine and Clinical Microbiology, Faculty of Allied Health Sciences, Chulalongkorn University, Pathumwan, Bangkok 10330, Thailand.
  • The Excellence Chulalongkorn Comprehensive Cancer Center, King Chulalongkorn Memorial Hospital, Pathumwan, Bangkok 10330, Thailand.

ORCID-Profile: Phumrapee Pianpaktr, Richard W Vachet, Trairak Pisitkun, Patanachai K Limpikirati

Förderung

  • NIGMS NIH HHS
  • Graduate School, Chulalongkorn University
  • Ministry of Higher Education, Science, Research and Innovation, Thailand

Zitieren

APA

Ramanandana, P., Pianpaktr, P., Makjaroen, J., Wongtangprasert, T., Kirsch, Z. J., Graban, E. M., Vachet, R. W., Somparn, P., Pisitkun, T., & Limpikirati, P. K. (2025). Mass Spectrometry-Driven Epitope Mapping: Application of Diethylpyrocarbonate Covalent Labeling for the Immunotherapeutic Target Programmed Cell Death Protein 1. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.5c00070

Vancouver

Ramanandana P, Pianpaktr P, Makjaroen J, Wongtangprasert T, Kirsch ZJ, Graban EM, et al. Mass Spectrometry-Driven Epitope Mapping: Application of Diethylpyrocarbonate Covalent Labeling for the Immunotherapeutic Target Programmed Cell Death Protein 1. Journal of the American Society for Mass Spectrometry. 2025. doi:10.1021/jasms.5c00070

BibTeX
@article{Ramanandana2025,
  author = {Ramanandana, Parawan and Pianpaktr, Phumrapee and Makjaroen, Jiradej and Wongtangprasert, Tossapon and Kirsch, Zachary J and Graban, Eric M and Vachet, Richard W and Somparn, Poorichaya and Pisitkun, Trairak and Limpikirati, Patanachai K},
  title = {Mass Spectrometry-Driven Epitope Mapping: Application of Diethylpyrocarbonate Covalent Labeling for the Immunotherapeutic Target Programmed Cell Death Protein 1},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {2025},
  doi = {10.1021/jasms.5c00070}
}
Kostenlos starten →